INTRODUCTION
The host immune response to foreign antigens in higher vertebrates has evolved via separate cell lineages, such as immunoglobulin-producing B cells, effectors T cells, and a variety of accessory cells specialized in antigen processing and presentation (antigen presenting cells, APC). B cells can produce antigen specific antibodies without (T independent, TI) or with (T-dependent, TD) T cell help 1 . The latter response is characterized by a process of progressive refinement of the antibody by selecting the type of immunoglobulin heavy chain (class switch recombination, CSR) and improving the affinity of the antigen binding site (affinity maturation). This process entails genetic alterations of the DNA sequences of the immunoglobulin genes; excision of intervening heavy chain sequences in CSR and mutation of nucleotides in the antigen-binding region (somatic hypermutation, SHM), a process followed by selection, resulting in affinity maturation. SHM and CSR take place in a lymphoid structure called Germinal Center (GC). Typically, cognate T-B interactions with APC and antigen occur at the border of primary lymphoid follicles 2 . Then, antigen-stimulated B cells enter the GC and experience a proliferative burst, mostly with unmutated Ig genes [3] [4] [5] , followed by the onset of SHM and CSR, resulting in clonal selection of class switched B cells carrying multiple mutations of their high affinity antibodies 3, 4, [6] [7] [8] . Transit of GC centroblasts from the dark zone to the light zone of the GC may signal two different phases of the generation and selection of high affinity Ig carrying B cells 9, 10 .
only.
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The TI response in mice is typically extrafollicular 11 , unmutated 12 and with no or short transit through a GC reaction [13] [14] [15] . Recently, evidence of hypermutated memory B cells without GC transit has been identified in humans 16, 17 and mice 14 .
The gene expression changes which occur from the initial activation up to the GC exit have been extensively described [18] [19] [20] .
Genetic experiments have shown that Activation Induced Cytidine Deaminase (AID) is essential for both CSR and SHM 21 . AID is a 24 kDa molecule of the APOBEC family 22 restricted in its expression to lymphoid organs 22 and embryonic stem cells 23 . Two separate domains of the AID molecule are required for CSR and SHM, in cooperation with the DNA repair machinery 24 .
The mechanism by which AID performs SHM and CSR has been a matter of controversy, and is not resolved yet. The structural similarity with the APOBEC family, an RNAediting enzyme group of proteins, and other experimental evidence 25 suggests an indirect mechanism by which nuclear AID binds and edit the message of a yet unidentified endonuclease, export the mRNA into the cytoplasm for translation, then the endonuclease return to the nucleus where it binds to the DNA sequences 25, 26 . Other experiments suggest a direct DNA-binding activity of AID, together with co-factors 27 , resulting in a direct DNA deamination and consequent introduction of mutations upon activation of the DNA repair machinery 25, 28 . Consistent with both theories are experiments showing GFP-tagged transfected AID localizing to the nucleus in the presence of appropriate co-binding molecules 29, 30 .
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In situ hybridization and cDNA analysis of B cell fractions suggest that AID is expressed in GC 22, 31 . In addition, AID protein was detected in purified centroblast preparations by Western Blot 32 . Cellular fractionation shows AID to be largely in the cytoplasm 32 , with less than 10% possibly localized in the nucleus 25 .
AID expression is induced by antigen-and T-cell interactions with B cell surface receptors for interleukins (IL-4), bcr-associated co-stimulatory molecules (CD40) and
Toll-like receptors (TLR-4) [33] [34] [35] [36] [37] . E2A activity is necessary for AID expression, which is in turn negatively influenced by BHLH proteins such as Id2 and Id3 35, 36 .
Recently, a rat monoclonal antibody specifically recognizing AID in human fixed tissue has been described 31 . Here we present a detailed analysis of the distribution of AID in normal human lymphoid tissues, its environmental context within and outside the GC and a description of the subcellular localization of this protein in vivo.
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MATERIALS AND METHOD
Patients
Paraffin embedded normal lymphoid tissues (14 lymph nodes, 10 tonsils, 3 spleens) were obtained from the files of the Department of Pathology, Columbia University Medical
Center, New York, according to Columbia University and federal provisions.
Tissue microarray (TMA) containing multiple normal tonsil samples was constructed using Beecher Instruments microarrayer (Silver Spring, MD) as published in details 38 . At least three samples were used in each staining experiment and results were duplicated in two independent institutions (U.S.A. and Germany).
Cell lines and in vitro stimulation.
Cell lines were grown in vitro and stimulated with CD40L-or mock-transfectants, or anti IgM (10 µg/ml for 12 or 21h) as previously published 39 . EBNA2 conditional cell line ER-EB was grown with or without estrogen as published 40 . Hydrogen peroxide treatment at 0, 100, 500 and 1,000 µM 41 was applied for 6h in culture and monitored for AnnexinV binding and H2AX foci formation. Cells were fixed, embedded in molten agar and processed similar to fresh surgical specimens.
Immunohistochemistry.
only. For selective detection of nuclear AID, sections were stained first with CD20 antibody and fully developed in immunoperoxidase with AEC, thus preventing any further staining of the membrane or cytoplasm of the heavily stained CD20+ cells, and leaving the nucleus unstained. Then EK2-5G9 or a control antibody (rabbit CD79a or rat CD45RA) was applied and developed in Alkaline Phosphatase as described above.
In order to exclude artifactual, processing-dependent nuclear re-localization of AID, all specimens were co-stained in double IF and IHC for proteins of small molecular weight and known subcellular distribution (e.g. CCL22: 2.9 kDa, CD20: 33-36 kDa, PCNA: 36 kDa) and the correct localization verified. Furthermore, we co-stained AID with cREL (75 kDa), previously shown to be translocated into the nucleus selectively and specifically dependent on CD40 signaling 39 .
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RESULTS
Specificity and distribution of AID in normal lymphoid tissues.
The specificity of the staining pattern of the EK2-5G9 antibody (named anti-AID hereafter), matching the AID RNA in situ hybridization distribution 31 In tonsils and lymph nodes AID was found to be expressed in the dark and outer zones of the GC and in extrafollicular large cells, often with dendritic morphology 31 . AID+ cells of large and medium size were seen not only in the immediate vicinity of the follicular mantle, but also scattered in the interfollicular areas, and within the festooned tonsil epithelium, where marginal zone-type B cells normally reside 48 ( Fig. 1B-D) .
Comparison of lymph nodes with follicular vs. paracortical hyperplasia show parallel and concomitant increase in extrafollicular AID staining together with an increase in AID+ GC size (not shown).
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Spleens with and without marginal zone hyperplasia contained AID+ GC and scattered single cells in the marginal zone (not shown and 49 ). The follicular mantle was invariably AID-.
We found AID+ cells to be invariably PAX5+, CD3-, and Ki-67+. In the GC, positive cells in the dark zone (DZ) were CD20+, BCL6+, MTA3+, Oct-2+, bcl2-, IRF4-, PRDM1-, nuclear cREL-, and CDKN1B (p27, Kip1) negative ( A reproducible minority of the extrafollicular AID+ cells was CD30+, as well as occasional large blasts at the border of GC ( Fig. 2 C-E).
To define the transcriptional activity in the GC and extrafollicular AID+ cells, tonsils were co-stained for AID and proteins known to be associated with activation and B cell signaling 18, 39 . Extrafollicular AID+ cells were E47+, Id2-, occasionally cMYC+, JunB+ and CCL22+, and largely negative for IRF4 ( Fig. 5 A-E). In the GC, AID+ cells were E47+, Id2-or borderline +, and negative for cMYC, CCL22, IRF4 
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In the GC and in the extrafollicular areas, nuclear staining was demonstrated by both immunofluorescence and immunohistochemistry methods, mostly, but not always, associated with strong cytoplasmic AID staining (cytAID) (Fig. 2 B, E; Fig. 3 ). Nuclear AID (nAID) was prominent in larger extrafollicular cells, averaging 14.4% ± 3.9% (n=5) of the total extrafollicular AID+ population, which represents up to 1% of the extrafollicular lymphocytes (Fig. 3C ). In the GC, nAID was weaker and expressed in smaller centroblasts, sometimes with irregular contours, often with faint cytoplasmic staining. 2.5% ± 1.2% GC cells were nAID positive, irrespective of the size of the GC (n= 16; r= 0.92) (Fig. 3 C) . The percentage of nAID in the OZ was 20-30% higher than in the DZ (not shown).
Confocal microscopy confirmed nuclear deposition of nAID staining in a chromatin-like texture pattern (Fig. 3C ).
To gain insight into the cellular environment during AID nuclear translocation, we differentially examined nAID and cytAID cells.
Extrafollicular nAID+ cells were 50% weakly positive for CD30 (Fig. 2E ), 30% CCNB1+ (not shown), negative for nuclear cREL (Fig. 3 A,B) , BCL6, CDKN1B and TP53, and did not contain foci of H2AX or phosphorylated H2B histones (not shown).
Outside the GC, cytAID+ cells were also Ki-67+, CCNB1-, BCL6-, CDKN1B-and rarely TP53+ (Fig. 6 ). TP53 was also occasionally seen in CD30+ cells (not shown) and in cytAID+ at the border of the GC (Fig. 6 ).
Dark zone nAID+ cells were often BCL6 weak, but invariably Ki-67+, mostly CDKN1B- (Fig.6 ), TP53-. CCNB1, which strongly stained the nucleus and cytoplasm of larger centroblasts, and did not stain smaller nAID+ cells (Fig. 6 ). The surrounding cytAID+ only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From cells were brightly BCL6+ and shared the same remaining phenotype, plus variable expression of membranous CCNB1 (Fig. 6 ). H2AX or phosphorylated H2B histones were negative in both.
In the outer zone, AID+ cells had a more variegated phenotype. Similar to the DZ, OZ nAID+ cells were weakly BCL6+ , Ki-67+, CDKN1B-, TP53-, and CCNB1-. CytAID+ cells were also variably BCL6+, largely Ki-67+, cytoplasmic CCNB1+, but occasionally double positive for CDKN1B and Ki-67, both weakly (Fig. 6) . No H2AX or phosphorylated H2B histone foci were seen.
In vitro manipulation of AID nuclear translocation.
Primary virgin B cells and GC blasts are both unsuitable for in vitro reproduction of GC physiology. To understand the signals which may induce nuclear AID translocation we challenged two GC-derived ABC-type and one GC-type human B-cell lymphoma lines (OCY-Ly3: nAID 0.55%; OCY-Ly10:nAID 1.5%, Ramos : nAID 0.5%) with CD40-bearing or mock-transfected fibroblasts 39 . No increase of nAID was noticed, whereas a modest increase in cytoplasmic staining was seen in those and in 2 other DLBCL lines For
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we used one of those to further explore a surrogate of combined CD40 and bcr signaling.
The ER-EB lymphoblastoid cell line (nAID 0.01%) was conditionally induced into quiescence or EBNA2-dependent LMP1 and LMP2a signalling 40, 55 . No change in nAID was seen upon EBV activation or withdrawal.
For
DISCUSSION
It is unclear whether AID edits DNA directly by binding to it or through editing the RNA coding for an unknown endonuclease 22, 26, 56 , either way, this requires a phase of AID localization in the nucleus 26 . Indeed, tagged and transfected AID has been shown to transiently enter the nucleus, but then actively prevented from lingering there 29, 30 . In addition, transfected AID increases the mutation rate of target sequences several folds 30, 57, 58 and binds to actively transcribed DNA regions 56 , where it can be coprecipitated with members of the DNA transcription machinery. Therefore, it is not surprising that we were able to show in GC, a small subset (<3%) of small centroblasts and extrafollicular blasts (11%) displaying nuclear positivity.
The percentage of nAID positive cells depends on several factors. The first factor is how long AID stays in the nucleus, how rapidly it moves out, and how often it shuttles between the nucleus and the cytoplasm in a given mutation cycle. In primary cells, this parameter is unknown. There seems to be a consensus that AID is safely kept in the cytoplasm most of the time, however, increasing its nuclear permanence does not seems to affect the mutation rate of physiologic targets 29 . This is, possibly, because B-cell specific co-factors shuttle AID into the nucleus and bring it to the correct target DNA sequence 27 .
The second factor is the mutation rate of the cell where AID nuclear relocation causes the DNA breaks. The mutation rate of the approximately 1Kb long heavy and light chain only.
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targets in the immune response to a specific antigen has been estimated to be up to 1x10 -3 per base pair per generation 59 . Hence, each mutating GC cell must have nuclear AID at some point during each cell cycle (lasting 6 hrs in centroblasts 60 ). A single nucleotide mutation is introduced per cell cycle; therefore hypermutating cells must experience nuclear AID several times during their permanence in the GC.
The third factor is clonal representation in the population analyzed. Each clone is defined as multiple cells with identical mutation repertoire, belonging to a "lineage tree", system, which we believe is in the range of 500 molecules per cell (e.g. IL-2Rß or cMYC we detected by IHC, average 500-1,000 molecules/cell 19, 63, 64 ).
Cells undergoing CSR may also contribute to the percentage of nuclear AID+ cells in the GC, and having a larger target, may load more AID molecules in the nucleus. RAG molecules, which analogously target a DNA segment of similar size, can indeed be detected in the nucleus of thymocytes and BM B cells 65 .
CSR has been localized in the tonsils in GC cells putatively identified as "centrocytes" 66 .
The excised switched DNA circles characterizing those cells can be identified in at least 1 in 500 of the cells in the "bm4" fraction (light density, CD38+, CD77-, IgD± tonsil cells 66 ), similar in frequency to the nAID+ cells detected. We did not find, however, evidence of DNA breaks in nAID+ cells by using phosphorylated histone staining. 67 replication is required for AID to reach its target, but its presence is not desirable when mutations are repaired or when the cell is ready to exit from an actively cycling state.
We finally sought to investigate the effect of known AID-inducing stimuli on cytoplasmic intensity versus nuclear relocation. None of these altered the percentage of nAID, suggesting that de novo AID induction and nuclear translocation respond to a separate and different set of stimuli. A more physiologic model is, however, needed to clarify these issues.
In summary, the GC nAID+ cells we have identified may represent cells undergoing CSR, SHM or both, but it is not clear in which proportion, or whether the actual nucleotide replacement occurs after one cell cycle in a nAID-negative cell.
The apical and basal light zone, where centrocytes encounter T cells and immunocomplex-bearing FDC, and where affinity maturation may take place 50, 66 , are devoid of significant amount of AID and its driving factors (e.g. E47) 71, 72 . Instead, AID is found in DZ and OZ, two distinct, but contiguous zones located at the opposite poles of the polarized GC.
DZ centroblasts comprise rather homogeneous and highly proliferating clones of IgDnegative B cells; on the contrary, OZ is composed of a heterogeneous mixture of proliferating large and small AID+ and AID-B cells, T-lymphocytes and plasmacytoid cells 66 . It is morphologically elusive unless CD23 immunohistochemistry is performed, and too close to the mantle zone to be sampled separately from the apical light zone 4 .
AID and optimal IgD staining reproducibly identifies the OZ and at the same time 79 , bear a more robust signature of T-cell dependent, CD40-and IL4-mediated B-cell activation (cMYC+, CCL22+, IRF4+, JunB+) 18 , which has been shown to be necessary for AID induction 33, 80 . The relationship between the CD30+ cells and the extrafollicular AID+ cells is circumstantial but is suggested by 2 facts: the presence of a phenotypic continuum between the 2 populations, which is not shared by any other extrafollicular B cell population, and the fact that the nAID population has the highest frequency of double CD30+ AID+. Thus, we assume that the antigen-and Tdependent reaction generate a burst of CD30+ B cells, which in turn produce an AID+ only.
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progeny in which mutation may start. The destiny of such progeny would be to rapidly enter the GC reaction or to generate an extrafollicular response.
Interestingly, another population of mutated large CD20+, IRF4+, CD30-B cells with dendritic morphology (LBC-DM) has been described 81 . AID+ interfollicular cells are instead CD20+, IRF4-, highly proliferating, and occasionally CD30+. More studies are needed to define the relationship between these 2 populations.
The nuclear localization of AID we demonstrate in this study will not solve the controversy of the mechanism by which AID acts. We found nucleolar exclusion of this protein, but further and more detailed studies are necessary. The predominant expression of AID in the cytoplasm remains to be explained; this may represent a reservoir, actively prevented from entering the nucleus except when needed, similar to NFkB complexes 82 , or, alternatively, AID has an independent cytoplasmic function, yet to be discovered.
The established concepts of SHM and CSR location inside the GC are once more validated by our findings, although we suggest a more precise distribution within the GC zones. Whether AID extrafollicular expression is linked to the initiation of SHM or to a GC-independent CSR remains a question open for further investigation.
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